Results 241 to 250 of about 168,862 (349)

Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo

, 2013
Ryan S. Soderquist, Darcy Bates, Alexey V. Danilov, Alan Eastman   +3 more
openalex   +1 more source

Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia

, 2017
José Sandoval-Sus, Julio C. Chávez, Samir Dalia, Syeda Mahrukh Hussnain Naqvi, Chetasi Talati, Lisa Nodzon, Mohamed A. Kharfan‐Dabaja, Javier Pinilla‐Ibarz   +7 more
openalex   +2 more sources

Considerations for the practical management of cardiovascular risk with Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia. [PDF]

Oncologist
Lenihan D, Bloom M, Copeland-Halperin R, Fleming MR, Fradley M, O'Quinn R, Bhat SA.   +6 more
europepmc   +1 more source

Anti‐inflammatory effects of physical stimuli: The central role of networks in shaping the future of pharmacological research

British Journal of Pharmacology, EarlyView.
Addressing complexity in the study of life sciences through Systems Biology and Systems Medicine has been transformative, making Systems Pharmacology the next logical step. In this review, we focus on physical stimuli, whose potential in pharmacology has been neglected, despite demonstrated therapeutic properties.
Veronica Paparozzi, Reyhaneh Hooshmandabbasi, Alessandro Ravoni, Ying Ma, Luigi Manni, Timothy J. Koh, Caroline Maake, Tiziana Guarnieri, Darong Lai, Vitalii Zablotskii, Christine Nardini   +10 more
wiley   +1 more source

Hope for high risk chronic lymphocytic leukemia after ibrutinib failure

, 2018
Ohad Benjamini
openalex   +1 more source

From Genomic and Epigenomic Maps to Medicines in Adult T‐Cell Leukemia/Lymphoma

Cancer Science, EarlyView.
ABSTRACT Adult T‐cell leukemia/lymphoma (ATL) is an aggressive and refractory hematologic malignancy that is caused by human T‐cell leukemia virus type‐1 (HTLV‐1) retrovirus. ATL results from a combination of viral latency and the accumulation of abnormalities throughout the genome, epigenome, transcriptome, and signaling pathways.
Kako Suzuki, Makoto Yamagishi
wiley   +1 more source

Real-world cardiovascular risks of ibrutinib in chronic lymphocytic leukemia: a retrospective study. [PDF]

Front Oncol
Ivanovic J, Otasevic V, Markovic K, Vukovic V, Bibic T, Tomic Vujovic K, Kozarac S, Vladicic Masic J, Milic N, Kulic J, Antic D.   +10 more
europepmc   +1 more source

Homoharringtonine Promotes FTO Degradation to Suppress LILRB4‐Mediated Immune Evasion in Acute Monocytic Leukaemia

Cell Proliferation, EarlyView.
Homoharringtonine (HHT) suppresses immune evasion in acute monocytic leukaemia (AML‐M5) by attenuating the FTO/m6A/LILRB4 axis, thereby enhancing CD8+ T cell cytotoxicity. ABSTRACT Acute monocytic leukaemia, a subtype of acute myeloid leukaemia (AML), is a highly aggressive malignancy characterised by a poor prognosis, primarily due to the ability of ...
Fangfang Huang, Xiang Luo, Mengyu Zhang, Le Jin, Wenxin Sun, Peihan Chen, Xiuli Hong, Chenyu Xu, Meizhi Jiang, Die Hu, Bin Zhang, Shengwei Hu, Chuanjiang Yang, Rui Gao, Jinzhang Zeng, Quanyi Lu, Qiang Luo, Jun Wu, Siming Chen   +18 more
wiley   +1 more source

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy. [PDF]

Cancers (Basel)
Molica S, Allsup D.
europepmc   +1 more source

Chronic lymphocytic leukemia.

Experimental oncology, 2013
openaire   +2 more sources